![Michael Pehl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Pehl
Amministratore Delegato presso ADCendo ApS
Posizioni attive di Michael Pehl
Società | Posizione | Inizio | Fine |
---|---|---|---|
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Amministratore Delegato | 07/07/2021 | - |
Storia della carriera di Michael Pehl
Precedenti posizioni note di Michael Pehl
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMMUNOMEDICS, INC. | Direttore/Membro del Consiglio | 07/12/2017 | 23/02/2019 |
Amministratore Delegato | 09/11/2017 | 23/02/2019 | |
Presidente | 07/12/2017 | 23/02/2019 | |
CELGENE | Corporate Officer/Principal | 01/01/2009 | 21/08/2017 |
GEMoaB Monoclonals GmbH
![]() GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Part of AvenCell Therapeutics, Inc., GEMoaB Monoclonals GmbH is a German company that manufactures biopharmaceutical products. The company is based in Dresden, Germany. The company was founded in 2014 by Gerhard Ehninger. GEMoaB Monoclonals was acquired by AvenCell Therapeutics, Inc. from Cellex Cell Professionals GmbH on March 30, 2022. | Amministratore Delegato | - | - |
Formazione di Michael Pehl
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Germania | 3 |
Danimarca | 2 |
Posizioni
Chief Executive Officer | 3 |
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Celgene Corp.
![]() Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Immunomedics, Inc.
![]() Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Health Technology |
GEMoaB Monoclonals GmbH
![]() GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Part of AvenCell Therapeutics, Inc., GEMoaB Monoclonals GmbH is a German company that manufactures biopharmaceutical products. The company is based in Dresden, Germany. The company was founded in 2014 by Gerhard Ehninger. GEMoaB Monoclonals was acquired by AvenCell Therapeutics, Inc. from Cellex Cell Professionals GmbH on March 30, 2022. | Health Technology |
- Borsa valori
- Insiders
- Michael Pehl
- Esperienza